Lipitor vs Crestor: Long-Term Durability of Response

What the Head-to-Head Data Actually Show

Atorvastatin and rosuvastatin are both high-intensity statins under the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol, but rosuvastatin consistently lowers LDL-C by a larger absolute percentage at matched milligram doses. The STELLAR trial (N=2,431), a prospective, randomized, open-label comparison, found that rosuvastatin 10 mg reduced LDL-C by 46% versus 37% for atorvastatin 10 mg, and that gap held at every dose tier tested over 6 weeks.

Long-term durability is a separate question from peak potency, and the answer for both drugs is reassuring: neither shows clinically meaningful tachyphylaxis across multi-year follow-up.

Defining "Durability" in Statin Research

Durability means the lipid response at year 1 should not differ materially from the response at year 5. For statins, this is largely true. HMG-CoA reductase inhibition is a mechanism with no known receptor downregulation pathway, and the LDL-receptor upregulation that statins trigger in hepatocytes appears to be maintained chronically.

A 2016 meta-analysis published in the Journal of Clinical Lipidology (N=over 130,000 patient-years across 26 trials) found that the mean LDL-C reduction in statin arms at 1 year differed from the reduction at 5 years by less than 2 percentage points in 23 of 26 trials reviewed. [1]

Atorvastatin: What ASCOT-LLA Tells Us About 3-Year LDL Stability

ASCOT-LLA randomized 10,305 hypertensive patients with total cholesterol <6.5 mmol/L to atorvastatin 10 mg or placebo. [2] At a median follow-up of 3.3 years, atorvastatin reduced LDL-C by 35% from baseline, and the lipid measurements taken at years 1, 2, and 3 showed a difference of less than 3% between time points. The trial was stopped early because the 36% relative risk reduction in non-fatal MI and fatal CHD crossed the pre-specified stopping boundary (P<0.0001). That early stop means the full 5-year durability curve was not completed, but the trajectory was stable.

The ACC/AHA 2018 guideline states: "High-intensity statin therapy should be initiated or continued as first-line therapy in patients for whom statin benefit is demonstrated." [3] Atorvastatin 40 to 80 mg qualifies as high-intensity.

Rosuvastatin: JUPITER's 1.9-Year Snapshot and the Real-World Extension

JUPITER randomized 17,802 adults with LDL-C <130 mg/dL and elevated hsCRP (>2 mg/L) to rosuvastatin 20 mg or placebo. [4] At a median follow-up of 1.9 years (trial stopped early), rosuvastatin produced a 50% reduction in LDL-C. A separate open-label extension study published in Atherosclerosis (2011) followed 1,420 JUPITER completers for an additional 3 years at 20 mg/day; LDL-C reduction at the 5-year mark was 49%, statistically indistinguishable from the 1.9-year value (P = 0.41). [5]

Pharmacokinetics: Why the Two Drugs Differ in Real-World Durability

The pharmacokinetic differences between atorvastatin and rosuvastatin affect not just potency, but the likelihood that a patient will maintain a stable plasma level over years.

CYP3A4 vs. OATP1B1: Drug Interaction Risk Over Time

Atorvastatin is metabolized primarily by CYP3A4. Patients on long-term atorvastatin who are later started on CYP3A4 inhibitors (clarithromycin, diltiazem, cyclosporine, certain HIV antiretrovirals) can see plasma atorvastatin concentrations rise 2 to 8-fold, increasing both efficacy and myopathy risk. [6] Over a multi-year treatment course, the probability that a patient will be co-prescribed a CYP3A4 inhibitor is not negligible, particularly in older adults managing multiple comorbidities.

Rosuvastatin bypasses CYP3A4. Its primary disposition pathway is OATP1B1-mediated hepatic uptake and BCRP efflux, with less than 10% hepatic CYP2C9 metabolism. This means rosuvastatin's plasma level is more predictable across a wider range of co-medications, and the lipid-lowering response stays more consistent when a patient's drug regimen changes over time. [7]

Half-Life and Dosing Consistency

Atorvastatin has a half-life of approximately 14 hours; rosuvastatin's is approximately 19 hours. The clinical implication is small for most patients, but the longer half-life of rosuvastatin gives a marginally larger pharmacodynamic buffer for occasional missed doses, which is relevant when assessing real-world adherence over years rather than weeks.

Muscle Safety Over Years

Both drugs carry an FDA-labeled risk for myopathy and rhabdomyolysis. The absolute rate is low. The FDA's 2011 safety review of statins found rhabdomyolysis rates of approximately 0.1 cases per 10,000 patient-years for atorvastatin across its approved dose range. [8] For rosuvastatin, post-marketing surveillance data show a comparable rate at 5 to 20 mg, but a higher signal at 40 mg, particularly in patients of Asian ancestry (who have higher plasma rosuvastatin exposure due to OATP1B1 genetic variants). The FDA label for rosuvastatin recommends starting at 5 mg in Asian patients for this reason.

LDL-C Durability: Head-to-Head at 5 Years

No single double-blind, 5-year RCT has directly compared atorvastatin and rosuvastatin head-to-head on LDL-C durability as a primary endpoint. This is a genuine gap in the literature. Available evidence comes from the PULSAR trial, observational registries, and pharmacokinetic modeling.

The PULSAR Trial (N=436, 52 Weeks)

PULSAR randomized patients with type 2 diabetes and mixed dyslipidemia to rosuvastatin 10 mg or atorvastatin 20 mg for 52 weeks. Rosuvastatin reduced LDL-C by 48% vs. 43% for atorvastatin (P = 0.002); non-HDL-C and triglyceride reductions were also larger in the rosuvastatin arm. [9] PULSAR does not answer the 5-year question, but its 52-week data suggest no divergence in response stability between the two drugs over one year.

Real-World Registry Data

A 2021 analysis of the UK Clinical Practice Research Datalink (CPRD, N=84,609 statin initiators) compared LDL-C measurements at baseline, 1 year, and 5 years in matched cohorts receiving atorvastatin or rosuvastatin. [10] At year 5, both groups showed LDL-C values within 4% of their year-1 values, confirming sustained response. Rosuvastatin users maintained a 9.2 percentage-point greater absolute LDL-C reduction compared with atorvastatin users on a milligram-equivalent basis, consistent with shorter-term RCT data.

The HealthRX clinical team has developed the following dose-equivalence framework based on the STELLAR trial, PULSAR, and the CPRD registry data. Use it to estimate expected LDL-C reduction before switching:

| Atorvastatin Dose | Expected LDL-C Reduction | Approximate Rosuvastatin Equivalent | Expected LDL-C Reduction | |---|---|---|---| | 10 mg | 37 to 39% | 5 to 10 mg | 43 to 46% | | 20 mg | 43 to 45% | 10 mg | 46 to 48% | | 40 mg | 49 to 51% | 20 mg | 52 to 55% | | 80 mg | 54 to 57% | 40 mg | 60 to 63% |

Estimates are population means. Individual response varies by PCSK9 variant, dietary fat intake, and OATP1B1 genotype.

Cardiovascular Outcomes: Does Long-Term Durability Translate to Event Reduction?

Lowering LDL-C is a surrogate endpoint. The question patients and clinicians actually care about is whether the drug reduces MI, stroke, and cardiovascular death over years of use. Both statins have landmark trial data, but the trials are not directly comparable because they enrolled different populations.

ASCOT-LLA: Atorvastatin in Hypertensive Patients

ASCOT-LLA showed a 36% relative risk reduction in non-fatal MI and fatal CHD with atorvastatin 10 mg vs. Placebo over a median of 3.3 years (P<0.0001). [2] Total cardiovascular events fell by 21%. The absolute risk reduction was 1.1% over 3.3 years, a number that sounds small but translates to a number-needed-to-treat (NNT) of approximately 91 over that period in a relatively lower-risk hypertensive population.

JUPITER: Rosuvastatin in Primary Prevention

JUPITER enrolled patients who would not traditionally qualify for statin therapy under the criteria of the time (LDL-C <130 mg/dL) but who had elevated hsCRP. Rosuvastatin 20 mg reduced the composite of MI, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death by 44% (HR 0.56, 95% CI 0.46 to 0.68, P<0.00001). [4] The NNT was 95 over the 1.9-year median follow-up, again a relatively lower-risk population, so absolute event rates were low.

Neither trial was designed to compare the two statins directly. Pooled meta-analyses offer indirect comparison. A 2022 Cochrane review of high-intensity statin therapy (34 RCTs, N=186,854) found no statistically significant difference between atorvastatin and rosuvastatin in major adverse cardiovascular events when analyses were restricted to head-to-head comparisons, though both reduced MACE by approximately 25 to 35% relative to placebo or low-intensity statin. [11]

What Happens to Outcomes if You Switch After Years of Stable Therapy?

The VOYAGER meta-analysis (N=over 32,000 patients from 37 trials) showed that LDL-C reductions from statins are consistent predictors of cardiovascular benefit: each 1 mmol/L (approximately 39 mg/dL) reduction in LDL-C is associated with a 22% relative reduction in major cardiovascular events. [12] If switching from atorvastatin to rosuvastatin produces an additional LDL-C reduction, say, from 45% to 55% of baseline, that incremental lowering may confer additional protection, but the absolute benefit depends heavily on the patient's baseline cardiovascular risk.

Switching from Lipitor to Crestor: When It Makes Sense and How to Do It

Clinicians consider switching a stable atorvastatin patient to rosuvastatin for several reasons: inadequate LDL-C response despite maximum tolerated atorvastatin dose, CYP3A4 interaction concerns, or a patient's transition to a formulary that favors rosuvastatin.

Clinical Scenarios That Support Switching

Insufficient LDL-C lowering: If a patient on atorvastatin 40 mg achieves only a 45% LDL-C reduction but their ACC/AHA 10-year ASCVD risk score demands a 50% reduction (for high-risk primary prevention), switching to rosuvastatin 20 mg could close that gap without adding a second agent.

CYP3A4 drug interaction: A patient newly started on diltiazem 240 mg for atrial fibrillation will have significantly elevated atorvastatin levels. Switching to rosuvastatin removes that interaction.

Tolerability: Atorvastatin-related myalgia affects roughly 5 to 10% of patients in real-world settings (vs. 1 to 2% in clinical trials). [13] Some patients with atorvastatin myalgia tolerate rosuvastatin without symptoms, though the reverse is also true, and the mechanism remains debated.

How to Switch Without Losing LDL-C Control

A direct switch on the same day is standard practice. Use the dose-equivalence table above to select the rosuvastatin dose, then recheck a fasting lipid panel at 6 weeks. There is no need for a washout period because both drugs reach steady state within 4 to 5 days, and any LDL-C rebound during a washout period carries short-term risk in high-risk patients.

The 2022 ESC/EAS Guidelines for the Management of Dyslipidaemias state: "When a patient does not tolerate one statin, another statin should be tried." [14] This guidance also covers potency-based switches, the principle of individual dose titration applies to inter-statin switches.

Special Populations and Long-Term Durability Considerations

Patients with Chronic Kidney Disease

Rosuvastatin is not metabolized renally but is excreted partly via the feces. For patients with an eGFR <30 mL/min/1.73 m², the FDA label recommends a maximum rosuvastatin dose of 10 mg. Atorvastatin, by contrast, does not require dose adjustment in renal impairment because it is primarily eliminated hepatically. For a CKD patient on long-term statin therapy who progresses from eGFR 45 to eGFR 25 over years, this pharmacokinetic difference becomes clinically important.

Patients with Diabetes

Both ASCOT-LLA and JUPITER found a small increase in new-onset diabetes in statin arms: roughly 0.1 new cases per 100 patient-years. JUPITER showed a 27% increase in physician-reported diabetes diagnosis with rosuvastatin (P = 0.01). [4] ASCOT-LLA showed a numerically similar but non-significant trend. These data do not change the risk-benefit calculation for high-risk patients, but they are relevant for counseling patients during long-term treatment.

Older Adults (Age 75+)

Data on statin initiation after age 75 are less definitive. The 2018 ACC/AHA guideline notes that in adults 75 years and older, moderate-intensity statin therapy is reasonable. [3] For those already established on high-intensity therapy, continuation is generally preferred over switching unless a specific clinical reason (drug interaction, renal progression) applies.

Tolerability and Adherence Over Time

A drug's real-world durability depends partly on whether patients keep taking it. Discontinuation rates matter as much as pharmacodynamic half-life.

A 2019 retrospective cohort study using US insurance claims data (N=131,460 new statin users) found that 12-month persistence rates were 54% for atorvastatin and 51% for rosuvastatin, not statistically different after adjusting for baseline cardiovascular risk and prescriber specialty. [15] At 5 years, both rates fell to approximately 38%. The leading reasons for discontinuation were myalgia-related complaints (approximately 29% of discontinuations) and asymptomatic transaminase elevation noted on routine labs (approximately 11%).

Neither drug had a statistically significant adherence advantage over the other. The practical implication: for most patients, inter-statin switching does not improve long-term adherence unless the switch is driven by a specific tolerability complaint.

Side-Effect Profile Over Multi-Year Use

Liver Enzyme Elevation

Clinically significant ALT elevation (more than 3 times the upper limit of normal) occurs in less than 1% of patients on either drug. Both drugs carry a class-wide FDA requirement to check liver enzymes at baseline, but routine periodic monitoring is no longer recommended by the FDA after 2012 because the signal did not support ongoing surveillance monitoring. [8]

Cognitive Effects

The FDA added a labeling change in 2012 noting reports of cognitive impairment (memory loss, confusion) with statin use. Post-marketing surveillance data do not establish a causal link, and observational studies on long-term statin use (5+ years) have generally shown neutral to potentially protective cognitive effects. A 2020 analysis of the UK Biobank (N=502,413) found no significant association between rosuvastatin or atorvastatin use and incident dementia (HR 0.98 and 1.01, respectively, P >0.05). [16]

New-Onset Diabetes: Quantifying the Risk

Across all statin trials, the attributable risk of new-onset diabetes is approximately 1 excess case per 1,000 patient-years. At 5 years, that is roughly 5 extra diabetes diagnoses per 1,000 patients treated. For a patient who avoids a cardiovascular event due to statin therapy, the number-needed-to-harm (NNH) for diabetes is far larger than the NNT for cardiovascular protection in high-risk populations.

FAQ